Diagnostics Program, PATH, Seattle, WA, USA.
Malaria and Neglected Tropical Diseases, PATH, Seattle, WA, USA.
BMC Infect Dis. 2022 Feb 4;22(1):121. doi: 10.1186/s12879-021-07023-5.
A new more highly sensitive rapid diagnostic test (HS-RDT) for Plasmodium falciparum malaria (Alere™/Abbott Malaria Ag P.f RDT [05FK140], now called NxTek™ Eliminate Malaria Ag Pf) was launched in 2017. The test has already been used in many research studies in a wide range of geographies and use cases.
In this study, we collate all published and available unpublished studies that use the HS-RDT and assess its performance in (i) prevalence surveys, (ii) clinical diagnosis, (iii) screening pregnant women, and (iv) active case detection. Two individual-level data sets from asymptomatic populations are used to fit logistic regression models to estimate the probability of HS-RDT positivity based on histidine-rich protein 2 (HRP2) concentration and parasite density. The performance of the HS-RDT in prevalence surveys is estimated by calculating the sensitivity and positive proportion in comparison to polymerase chain reaction (PCR) and conventional malaria RDTs.
We find that across 18 studies, in prevalence surveys, the mean sensitivity of the HS-RDT is estimated to be 56.1% (95% confidence interval [CI] 46.9-65.4%) compared to 44.3% (95% CI 32.6-56.0%) for a conventional RDT (co-RDT) when using nucleic acid amplification techniques as the reference standard. In studies where prevalence was estimated using both the HS-RDT and a co-RDT, we found that prevalence was on average 46% higher using a HS-RDT compared to a co-RDT. For use in clinical diagnosis and screening pregnant women, the HS-RDT was not significantly more sensitive than a co-RDT.
Overall, the evidence presented here suggests that the HS-RDT is more sensitive in asymptomatic populations and could provide a marginal improvement in clinical diagnosis and screening pregnant women. Although the HS-RDT has limited temperature stability and shelf-life claims compared to co-RDTs, there is no evidence to suggest, given this test has the same cost as current RDTs, it would have any negative impacts in terms of malaria misdiagnosis if it were widely used in all four population groups explored here.
一种新的、更高灵敏度的快速诊断检测方法(HS-RDT)用于检测恶性疟原虫疟疾(Alere/Abbott Malaria Ag P.f RDT[05FK140],现称为 NxTek™Eliminate Malaria Ag Pf)于 2017 年推出。该检测方法已经在许多不同地理位置和使用案例的研究中使用。
在这项研究中,我们汇集了所有使用 HS-RDT 的已发表和未发表的研究,并评估了其在以下方面的性能:(i)患病率调查,(ii)临床诊断,(iii)孕妇筛查,以及(iv)主动病例检测。我们使用两个无症状人群的个体水平数据集,拟合逻辑回归模型,根据高变区 2(HRP2)浓度和寄生虫密度来估计 HS-RDT 阳性的概率。通过比较聚合酶链反应(PCR)和常规疟疾 RDT,来计算患病率调查中 HS-RDT 的敏感性和阳性比例,以此来评估 HS-RDT 的性能。
我们发现,在 18 项研究中,在患病率调查中,与常规 RDT(co-RDT)相比,使用核酸扩增技术作为参考标准时,HS-RDT 的平均敏感性估计为 56.1%(95%置信区间[CI] 46.9-65.4%)。在使用 HS-RDT 和 co-RDT 估计患病率的研究中,我们发现使用 HS-RDT 时,患病率平均比 co-RDT 高 46%。在临床诊断和孕妇筛查中,HS-RDT 的敏感性并不比 co-RDT 高。
总体而言,这里提供的证据表明,HS-RDT 在无症状人群中更敏感,并且可以在临床诊断和孕妇筛查方面提供一定程度的改善。尽管 HS-RDT 在温度稳定性和保质期方面的说法与 co-RDT 相比存在局限性,但没有证据表明,如果该检测方法与当前 RDT 成本相同,并在所有四个研究人群中广泛使用,那么在疟疾误诊方面不会产生任何负面影响。